New Horizon Health

New Horizon Health EV/FCF

Delisted·Feb 9, 2026

The EV/FCF (Enterprise Value to Free Cash Flow) of New Horizon Health (6606.HK) as of Oct 24, 2026 is -9.35. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -9.84 — a change of -4.96% (higher).

EV/FCF

-9.35

YoY

-4.96%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of New Horizon Health is 2022 -9.35 . EV/FCF (Enterprise Value to Free Cash Flow) of New Horizon Health was 2021 -9.84 . It decreases by -4.96% higher compared to the previous year.

The New Horizon Health EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
-77.64 CNY
Jan 1, 2019
-52.47 CNY
Jan 1, 2020
-41.52 CNY
Jan 1, 2021
-9.84 CNY
Jan 1, 2022
-9.35 CNY
The New Horizon Health EV/FCF history
YEAREV/FCFYoY
-9.35-4.96%
-9.84-76.29%
-41.52-20.88%
-52.47-32.42%
-77.64—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

New Horizon Health Stock analysis

What does New Horizon Health do? New Horizon Health Ltd. generates revenue through the distribution of its ColoClear and Pupu tube products via its own network, contracted sales organisations (CSOs), and e-platforms managed by healthcare clinics. The company also develops Youyou Tube, a stool-based self-checking gastric cancer screening test, and CerviClear, a non-invasive urine cervical cancer home screening test, which are currently under development. Its primary customers include healthcare clinics and end-users seeking non-invasive cancer screening solutions. The firm's product portfolio focuses on innovative medical screening tools, targeting the growing demand for accessible and user-friendly health diagnostics. By leveraging its internal sales channels and partnerships with CSOs, New Horizon Health Ltd. ensures broad market reach for its products. The company's development of Youyou Tube and CerviClear reflects its strategic emphasis on expanding into high-need areas of cancer prevention and early detection. Revenue streams are derived from the sale of ColoClear and Pupu tube products, with future potential from the commercialization of Youyou Tube and CerviClear once development is complete. The company's business model relies on direct and indirect sales channels to healthcare providers and consumers, positioning it within the medical diagnostics sector. New Horizon Health is one of the most popular companies on Eulerpool.

Frequently Asked Questions about New Horizon Health stock

EV/FCF (Enterprise Value to Free Cash Flow) of New Horizon Health is -9.35 in 2022.

EV/FCF (Enterprise Value to Free Cash Flow) of New Horizon Health changed from -9.84 to -9.35, representing a -4.96% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) New Horizon Health since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s New Horizon Health with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — New Horizon Health

All Key Metrics — New Horizon Health